Modern Etiotropic Therapy of Influenza and ARVI in Adult Patients with Premorbid Pathology

Abstract

An open comparative observational study of the clinical efficacy and safety of riamilovir (Triazavirin™) in patients over age 18 with influenza and acute respiratory viral infections (ARVIs) was conducted during the epidemic seasons of2016-2017 and 2017-2018. Clinical efficacy and safety of riamilovir (Triazavirin™) in groups of patients with influenza and ARVI was demonstrated. The use of riamilovir (Triazavirin™) allowed to achieve rapid positive dynamics in the management of febrile-intoxication and catarrhal-respiratory syndromes; it was equally effective in patients who did not immediately seek professional help.

Keywords

• influenza
• acute respiratory viral infection
• arvi
• patients with premorbid pathology
• riamilovir (triazavirin™)